| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Biology, University of North Carolina, Chapel Hill, North Carolina.
PURPOSE. Biochemical and genetic evidence suggests that overexpression of or mutations in myocilin within the cells of the aqueous humor outflow pathway play a significant role in the development of steroid-induced and several other open-angle glaucomas. As a baseline to understanding the normal and pathologic function of myocilin, we determined the subcellular localization of myocilin in steroid-treated human Schlemm’s canal endothelial (SC) cells.
METHODS. SC cells were grown to confluence, treated with dexamethasone for 10 days, and then stained using antibodies against myocilin, tubulin, or ß-COP (a specific golgi protein) or vital stains for endoplasmic reticulum (ER) and golgi. Brefeldin A (BFA) and nocodazol (NZ) were used to disrupt the golgi or microtubules.
RESULTS. The authors found that myocilin staining was (a) always centered around the centrosome, (b) very similar to the pattern seen with NBD-ceramide, (c) was disrupted in characteristic ways by BFA and NZ and (d) showed extensive colocalization with ß-COP.
CONCLUSIONS. Results indicate that myocilin is localized to the golgi in SC cells. Such localization is consistent with myocilin being processed for secretion but is also consistent with sequence analysis and other data that suggest that myocilin or myocilin mutations might be targeted to the cytoplasmic face of the golgi, and under some circumstances play a role in or interfere with golgi or vesicle function. How such interference could eventually lead to open angle glaucoma is discussed.
This article has been cited by other articles:
|
|
 |
|
  A. R. Shepard, N. Jacobson, J. C. Millar, I.-H. Pang, H. T. Steely, C. C. Searby, V. C. Sheffield, E. M. Stone, and A. F. Clark Glaucoma-causing myocilin mutants require the Peroxisomal targeting signal-1 receptor (PTS1R) to elevate intraocular pressure Hum. Mol. Genet., March 15, 2007; 16(6): 609 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Hewitt, S. L. Bennett, J. H. Fingert, R. L. Cooper, E. M. Stone, J. E. Craig, and D. A. Mackey The Optic Nerve Head in Myocilin Glaucoma Invest. Ophthalmol. Vis. Sci., January 1, 2007; 48(1): 238 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Fautsch, C. K. Bahler, A. M. Vrabel, K. G. Howell, N. Loewen, W. L. Teo, E. M. Poeschla, and D. H. Johnson Perfusion of His-Tagged Eukaryotic Myocilin Increases Outflow Resistance in Human Anterior Segments in the Presence of Aqueous Humor Invest. Ophthalmol. Vis. Sci., January 1, 2006; 47(1): 213 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Aroca-Aguilar, F. Sanchez-Sanchez, S. Ghosh, M. Coca-Prados, and J. Escribano Myocilin Mutations Causing Glaucoma Inhibit the Intracellular Endoproteolytic Cleavage of Myocilin between Amino Acids Arg226 and Ile227 J. Biol. Chem., June 3, 2005; 280(22): 21043 - 21051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu and D. Vollrath Reversal of mutant myocilin non-secretion and cell killing: implications for glaucoma Hum. Mol. Genet., June 1, 2004; 13(11): 1193 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Filla, X. Liu, T. D. Nguyen, J. R. Polansky, C. R. Brandt, P. L. Kaufman, and D. M. Peters In Vitro Localization of TIGR/MYOC in Trabecular Meshwork Extracellular Matrix and Binding to Fibronectin Invest. Ophthalmol. Vis. Sci., January 1, 2002; 43(1): 151 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Wentz-Hunter, J. Ueda, and B. Y. J. T. Yue Protein Interactions with Myocilin Invest. Ophthalmol. Vis. Sci., January 1, 2002; 43(1): 176 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Fautsch and D. H. Johnson Characterization of Myocilin-Myocilin Interactions Invest. Ophthalmol. Vis. Sci., September 1, 2001; 42(10): 2324 - 2331. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
